Loss of X chromosome predicts favorable prognosis in female patients with t(8;21) acute myeloid leukemia

References

• Chou FS, Griesinger A, Wunderlich M, et al. The thrombopoietin/MPL/Bcl-xL pathway is essential for survival and self-renewal in human preleukemia induced by AML1-ETO. Blood. 2012;120(4):709–719.
   PubMed Web of Science ®Google Scholar
• Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447.
   PubMed Web of Science ®Google Scholar
• Rowley JD. Recurring chromosome abnormalities in leukemia and lymphoma. Semin Hematol. 1990;27(2):122–136.
   PubMed Web of Science ®Google Scholar
• Grimwade D, Hills RK, Moorman AV, et al. on behalf of the National Cancer Research Institute Adult Leukaemia Working Group. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116(3):354–365.
   PubMed Web of Science ®Google Scholar
• Schlenk RF, Benner A, Krauter J, et al. Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. JCO. 2004;22(18):3741–3750.
   PubMed Web of Science ®Google Scholar
• Bacher U, Schanz J, Braulke F, et al. Rare cytogenetic abnormalities in myelodysplastic syndromes. Mediterr J Hematol Infect Dis. 2015;7(1):e2015034.
   PubMedGoogle Scholar
• Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002;100(13):4325–4336.
   PubMed Web of Science ®Google Scholar
• Appelbaum FR, Kopecky KJ, Tallman MS, et al. The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations. Br J Haematol. 2006;135(2):165–173.
   PubMed Web of Science ®Google Scholar
• Liu XP, Xue YP, Liu SH, et al. [An analysis of cytogenetic characteristics and prognosis of 189 t (8; 21) acute myeloid leukemia patients]. Zhonghua Nei ke za Zhi. 2006;45(11):918–921. Chinese.
   PubMedGoogle Scholar
• Ustun C, Morgan E, Moodie EEM, et al. Core-binding factor acute myeloid leukemia with t(8;21): risk factors and a novel scoring system (I-CBFit). Cancer Med. 2018;7(9):4447–4455.
   PubMed Web of Science ®Google Scholar
• Jung HA, Maeng CH, Park S, et al. Prognostic factor analysis in core-binding factor-positive acute myeloid leukemia. Anticancer Res. 2014;34(2):1037–1045.
   PubMed Web of Science ®Google Scholar
• El Aziz Abd El Ghafar A, El-Sakhawy Y, Safwat N, et al. Cytogenetic analysis of acute myeloid leukemia with t(8;21): its clinical correlation with loss of X chromosome and del (9q). J Appl Hematol. 2018;9:51–58.
   Google Scholar
• Krauth MT, Eder C, Alpermann T, et al. High number of additional genetic lesions in acute myeloid leukemia with t(8;21)/RUNX1-RUNX1T1: frequency and impact on clinical outcome. Leukemia. 2014;28(7):1449–1458.
   PubMed Web of Science ®Google Scholar
• Rege K, Swansbury GJ, Atra AA, et al. Disease features in acute myeloid leukemia with t(8;21)(q22;q22). Influence of age, secondary karyotype abnormalities, CD19 status, and extramedullary leukemia on survival. Leukemia & Lymphoma. 2000;40(1–2):67–77.
   PubMed Web of Science ®Google Scholar
• Nishii K, Usui E, Katayama N, et al. Characteristics of t(8;21) acute myeloid leukemia (AML) with additional chromosomal abnormality: concomitant trisomy 4 may constitute a distinctive subtype of t(8;21) AML. Leukemia. 2003;17(4):731–737.
   PubMed Web of Science ®Google Scholar
• Klein K, Kaspers G, Harrison CJ, et al. Clinical impact of additional cytogenetic aberrations, cKIT and RAS mutations, and treatment elements in pediatric t(8;21)-AML: results from an international retrospective study by the International Berlin-Frankfurt-Munster Study Group. JCO. 2015;33(36):4247–4258.
   PubMed Web of Science ®Google Scholar
• Marcucci G, Mrozek K, Ruppert AS, et al. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. JCO. 2005;23(24):5705–5717.
   PubMed Web of Science ®Google Scholar
• Zhou W, Chen G, Gong D, et al. Loss of the Y chromosome predicts a high relapse risk in younger adult male patients with t(8;21) acute myeloid leukemia on high-dose cytarabine consolidation therapy: a retrospective multicenter study. Leukemia & Lymphoma. 2019. DOI:10.1080/10428194.2019.1683734
   Web of Science ®Google Scholar
• Willatt L, Morgan SM, Shaffer LG, et al. ISCN 2009 an international system for human cytogenetic nomenclature. Hum Genet. 2009;126(4):603–604.
   Google Scholar
• Gabert J, Beillard E, van der Velden VH, et al. Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia. 2003;17(12):2318–2357.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. JCO. 2003;21(24):4642–4649.
   PubMed Web of Science ®Google Scholar
• Delgado J, Pereira A, Villamor N, et al. Survival analysis in hematologic malignancies: recommendations for clinicians. Haematologica. 2014;99(9):1410–1420.
   PubMed Web of Science ®Google Scholar
• Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48(3):452–458.
   PubMed Web of Science ®Google Scholar
• Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Contr Clin Trials. 1996;17(4):343–346.
   PubMedGoogle Scholar
• Miyawaki S, Ohtake S, Fujisawa S, et al. A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 Study. Blood. 2011;117(8):2366–2372.
   PubMed Web of Science ®Google Scholar
• Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med. 1994;331(14):896–903.
   PubMed Web of Science ®Google Scholar
• Gong D, Li W, Hu LD, et al. Comparison of clinical efficacy of cytarabine with different regimens in postremission consolidation therapy for adult t(8;21) AML patients: a multicenter retrospective study in China. Acta Haematol. 2016;136(4):201–209.
   PubMed Web of Science ®Google Scholar
• Magina KN, Pregartner G, Zebisch A, et al. Cytarabine dose in the consolidation treatment of AML: a systematic review and meta-analysis. Blood. 2017;130(7):946–948.
   PubMed Web of Science ®Google Scholar
• Paschka P, Dohner K. Core-binding factor acute myeloid leukemia: can we improve on HiDAC consolidation? Hematol Am Soc Hematol Educ Prog. 2013;2013(1):209–219.
   PubMedGoogle Scholar
• Allen C, Hills RK, Lamb K, et al. The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia. Leukemia. 2013;27(9):1891–1901.
   PubMed Web of Science ®Google Scholar
• Paschka P, Marcucci G, Ruppert AS, et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. JCO. 2006;24(24):3904–3911.
   PubMed Web of Science ®Google Scholar
• Cairoli R, Beghini A, Grillo G, et al. Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. Blood. 2006;107(9):3463–3468.
   PubMed Web of Science ®Google Scholar
• Yin JA, O’Brien MA, Hills RK, et al. Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial. Blood. 2012;120(14):2826–2835.
   PubMed Web of Science ®Google Scholar
• Voso MT, Ottone T, Lavorgna S, et al. MRD in AML: the role of new techniques. Front Oncol. 2019;9:655.
   PubMed Web of Science ®Google Scholar
• Jourdan E, Boissel N, Chevret S, et al. Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. Blood. 2013;121(12):2213–2223.
   PubMed Web of Science ®Google Scholar
• Zhu HH, Zhang XH, Qin YZ, et al. MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial. Blood. 2013;121(20):4056–4062.
   PubMed Web of Science ®Google Scholar
• Ayatollahi H, Shajiei A, Sadeghian MH, et al. Prognostic importance of C-KIT mutations in core binding factor acute myeloid leukemia: a systematic review. Hematol/Oncol Stem Cell Ther. 2017;10(1):1–7.
   PubMedGoogle Scholar